In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $15.94 down -0.87% from its previous closing price of $16.08. In other words, the price has decreased by -$0.87 from its previous closing price. On the day, 3.86 million shares were traded. TAK stock price reached its highest trading level at $16.04 during the session, while it also had its lowest trading level at $15.888.
Ratios:
For a deeper understanding of Takeda Pharmaceutical Co ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.91 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.18. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.61.
BofA Securities Upgraded its Neutral to Buy on March 16, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 09 ’25 when Lauren Rusckowski Duprey bought 29,619 shares for $14.22 per share.
Teresa Marie Bitetti bought 87,023 shares of TAK for $1,242,688 on Dec 05 ’25. On Dec 04 ’25, another insider, Giles Richard Platford, who serves as the President, Plasma-Derived Ther of the company, bought 58,421 shares for $14.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 53044346880 and an Enterprise Value of 4535767531520. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 202.28, and their Forward P/E ratio for the next fiscal year is 25.50. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.70 while its Price-to-Book (P/B) ratio in mrq is 1.04. Its current Enterprise Value per Revenue stands at 1.027 whereas that against EBITDA is 3.984.
Stock Price History:
The Beta on a monthly basis for TAK is 0.04, which has changed by 0.23787534 over the last 52 weeks, in comparison to a change of 0.12692177 over the same period for the S&P500. Over the past 52 weeks, TAK has reached a high of $16.48, while it has fallen to a 52-week low of $12.80. The 50-Day Moving Average of the stock is 6.42%, while the 200-Day Moving Average is calculated to be 8.18%.
Shares Statistics:
For the past three months, TAK has traded an average of 2.87M shares per day and 3384340 over the past ten days. A total of 3.16B shares are outstanding, with a floating share count of 3.16B. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.71% stake in the company. Shares short for TAK as of 1767139200 were 10385239 with a Short Ratio of 3.62, compared to 1764288000 on 11381864. Therefore, it implies a Short% of Shares Outstanding of 10385239 and a Short% of Float of 0.33000002.
Dividends & Splits
According to the company, the forward annual dividend rate for TAK is 0.32, from 198.0 in the trailing year. Against a Trailing Annual Dividend Yield of 12.313433. The stock’s 5-year Average Dividend Yield is 4.67.
Earnings Estimates
Analysts are recommending an EPS of between $51.16 and $51.16 for the fiscal current year, implying an average EPS of $51.16. EPS for the following year is $109.66, with 1.0 analysts recommending between $109.66 and $109.66.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $1.19T this quarter.It ranges from a high estimate of $1.26T to a low estimate of $1.15T. The current estimate, Takeda Pharmaceutical Co ADR’s year-ago sales were $1.14TFor the next quarter, 7 analysts are estimating revenue of $1.08T. There is a high estimate of $1.15T for the next quarter, whereas the lowest estimate is $1.03T.
A total of 15 analysts have provided revenue estimates for TAK’s current fiscal year. The highest revenue estimate was $4.58T, while the lowest revenue estimate was $4.45T, resulting in an average revenue estimate of $4.52T. In the same quarter a year ago, actual revenue was $580.36BBased on 15 analysts’ estimates, the company’s revenue will be $4.55T in the next fiscal year. The high estimate is $4.71T and the low estimate is $4.41T.
